Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

2.
3.

Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells.

Hendriks BS, Orr G, Wells A, Wiley HS, Lauffenburger DA.

J Biol Chem. 2005 Feb 18;280(7):6157-69. Epub 2004 Nov 29.

4.
5.

A mathematical model for the effects of HER2 overexpression on cell proliferation in breast cancer.

Eladdadi A, Isaacson D.

Bull Math Biol. 2008 Aug;70(6):1707-29. doi: 10.1007/s11538-008-9315-4. Epub 2008 Jul 22.

PMID:
18648887
6.

Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.

Paris L, Cecchetti S, Spadaro F, Abalsamo L, Lugini L, Pisanu ME, Iorio E, Natali PG, Ramoni C, Podo F.

Breast Cancer Res. 2010;12(3):R27. doi: 10.1186/bcr2575. Epub 2010 May 12.

7.

Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.

Huang Y, Li X, Jiang J, Frank SJ.

Oncogene. 2006 Dec 7;25(58):7565-76. Epub 2006 Jun 19.

PMID:
16785991
8.

Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.

Vazquez-Martin A, Colomer R, Brunet J, Lupu R, Menendez JA.

Cell Prolif. 2008 Feb;41(1):59-85. doi: 10.1111/j.1365-2184.2007.00498.x.

PMID:
18211286
9.

Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.

Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI.

Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):344-52.

PMID:
14751502
10.

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.

Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, Degenhardt Y, Rudolph SK, Haws TF Jr, Hudson-Curtis BL, Gilmer TM.

Cell Prolif. 2007 Aug;40(4):580-94.

PMID:
17635524
11.
12.

Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells.

Berquin IM, Pang B, Dziubinski ML, Scott LM, Chen YQ, Nolan GP, Ethier SP.

Oncogene. 2005 Apr 28;24(19):3177-86.

PMID:
15735691
13.

2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.

Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S, Miyakawa I, Agus DB, Koeffler HP.

Cancer. 2005 Dec 15;104(12):2701-8.

14.

Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer.

Fink-Retter A, Gschwantler-Kaulich D, Hudelist G, Mueller R, Kubista E, Czerwenka K, Singer CF.

Oncol Rep. 2007 Aug;18(2):299-304.

PMID:
17611648
15.

Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.

Forsberg S, Ostman A, Rollman O.

Arch Dermatol Res. 2008 Oct;300(9):505-16. doi: 10.1007/s00403-008-0853-2. Epub 2008 Apr 30.

PMID:
18446355
19.

Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly.

O'Rourke DM, Nute EJ, Davis JG, Wu C, Lee A, Murali R, Zhang HT, Qian X, Kao CC, Greene MI.

Oncogene. 1998 Mar 5;16(9):1197-207.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk